LUND, Sweden, April 29, 2025 —

First Quarter Results

• Net sales reached SEK 12.3 million (compared to 9.4 million SEK in the same period last year).
• The operating result was SEK -18.0 million (-18.4 million SEK in the same period last year).
• Earnings per share, both before and after dilution, totaled SEK -0.07 (-0.11 SEK in the same period last year).
• Cash flow from operating activities amounted to SEK -8.5 million (-7.3 million SEK in the same period last year).

CEO Claus Egstrand’s Comments

“The strong first quarter of 2025 clearly demonstrates Enzymatica’s progress and promising future. ColdZyme continues its strong performance in the pharmacy sector, outpacing the overall market growth and further increasing its market share. Sales in Sweden rose by 31.5%, and in the UK, they increased by 19.5% compared to the same period last year – clear evidence of ColdZyme’s reach and consumer satisfaction.

However, our home market sales are only a fraction of our future ambitions. Our patented technology provides a foundation for substantial sales growth through expansion into new markets and establishing strategic partnerships,” says Claus Egstrand, CEO.

Key Highlights During the Quarter

• On February 28, 2025, The Journal of Physiology published two independent studies on ColdZyme. Conducted at the University of Kent and the University in Vienna, the studies revealed that ColdZyme reduces viral load by 94% and alleviates cold symptoms. A clinical study involving 154 participants showed fewer sick days and milder symptoms. An in vitro study confirmed ColdZyme’s effectiveness in preventing viral infection in upper respiratory tract cells. These findings further validate ColdZyme’s therapeutic benefits.

Significant Events After the Quarter

• No significant events occurred after the quarter.

Other Events During and After the Quarter

Enzymatica hosted a press conference on March 5, 2025, available both in-person and online, where Professor Glen Davison and Professor Doris Wilflingseder presented their findings from the recently published article in *The Journal of Physiology*. Following the presentation, a company update was provided. Recordings of both are available on the company’s website.

Enzymatica is obligated to disclose the information contained in this press release under the EU Market Abuse Regulation. The information was submitted for publication through the contact person listed below on April 29, 2025, at 08:30 CET.

For further information, please contact:

Claus Egstrand, CEO, Enzymatica AB
Mobile: +44 7780 22 8385 | Email:

Enzymatica AB is based in Lund and is listed on the Nasdaq First North Growth Market. For more information, please visit .
Enzymatica’s Certified Adviser is Carnegie Investment Bank AB (publ).

This information was provided by Cision

The following files are available for download: